| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | One notable human pharmacokinetic study (Teichman et al. 2006, JCEM) demonstrating prolonged GH and IGF-1 elevation. Observational/Phase I design. No Phase III RCT. |
15 / 25 |
| Sample Size | Teichman 2006 enrolled 21 subjects. Additional small studies similarly tiny. Cumulative human sample in the tens. |
8 / 20 |
| Replication | The core PK findings have been referenced across literature, but independent replication of the Teichman result in separate cohorts is limited. Single research group essentially. |
10 / 20 |
| Journal Impact Factor | Teichman published in JCEM (IF ~6.5) — the best journal in the endocrinology space. This elevates the score despite limited study volume. |
4 / 15 |
| Funding Independence | ConjuChem (developer) funded early work. Some academic investigators. Predominantly developer-funded. |
4 / 10 |
| Population Diversity | 21 healthy adults — narrow, non-diverse population. Minimal score. |
1 / 5 |
| Researcher h-Index | Teichman et al. researchers have moderate profiles. Not prominently citable beyond this compound. |
2 / 5 |